ABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology

Related Keywords

Fremont ,California ,United States ,Australia ,Taiwan ,Thailand ,Khon Kaen ,Stanford University ,West Hollywood ,San Francisco ,Thai ,Australian ,Leeds Chow ,Scotta Irwin ,University Of California ,Australian Bellberry Human Research Ethics Committee ,Nasdaq ,Trademark Office ,Company Annual Report On Form ,Ethics Committee ,Company Quarterly Report On Form ,Sinai Medical Center ,Biopharma Inc ,Australian Therapeutic Goods Administration ,Khon Kaen University Of Thailand ,Exchange Commission ,Center Institutional Review Board ,Mahidol University ,University Of California At San Francisco ,Quarterly Report ,Clinical Trial Notification ,Ramathibodi Hospital ,Vitargus Phase ,Srinagarind Hospital ,Khon Kaen University ,Efficacy Study ,Adult Patients ,Attention Deficit Hyperactivity Disorder ,Medical Center Institutional Review Board ,Drug Administration ,Major Depressive Disorder ,Radix Polygalae ,Cedars Sinai Medical Center ,Institutional Review Board ,Principal Investigator ,For Vitargus ,Annual Report ,Quarterly Reports ,Months Ended September ,Abvc ,Iopharma ,Reports ,Third ,Quarter ,022 ,Financial ,Perational ,Results ,